Servier Completes Acquisition of Day One Biopharmaceuticals
Servier has completed its acquisition of Day One Biopharmaceuticals for $21.50 per share, valued at approximately $2.5 billion in equity. The deal strengthens Servier's position in oncology, particularly in pediatric low-grade glioma with the approved drug OJEMDATM (tovorafenib) and a pipeline targeting rare cancers. The acquisition supports Servier's long-term innovation goals under its Servier 2030 strategy.
Tickers: $DAWN
Topics: acquisition Day One Biopharmaceuticals oncology pharmaceutical industry Servier